Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) had its target price hoisted by equities researchers at HC Wainwright from $7.50 to $12.50 in a report issued on Monday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. HC Wainwright's price target would suggest a potential upside of 92.31% from the company's current price. HC Wainwright also issued estimates for Trevi Therapeutics' FY2024 earnings at ($0.48) EPS, Q1 2025 earnings at ($0.11) EPS, FY2026 earnings at ($0.57) EPS, FY2027 earnings at ($0.50) EPS, FY2028 earnings at ($0.39) EPS and FY2029 earnings at ($0.30) EPS.
Several other equities analysts have also recently commented on the company. Needham & Company LLC boosted their target price on Trevi Therapeutics from $8.00 to $25.00 and gave the stock a "buy" rating in a research report on Monday. Raymond James upgraded Trevi Therapeutics from an "outperform" rating to a "strong-buy" rating and boosted their target price for the stock from $9.00 to $29.00 in a research report on Monday. Finally, D. Boral Capital restated a "buy" rating and set a $21.00 target price on shares of Trevi Therapeutics in a research report on Friday, March 7th. Seven research analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $15.94.
Check Out Our Latest Research Report on TRVI
Trevi Therapeutics Trading Up 3.3 %
Shares of NASDAQ TRVI traded up $0.21 during mid-day trading on Monday, hitting $6.50. The company had a trading volume of 864,254 shares, compared to its average volume of 2,002,034. The company has a market capitalization of $499.63 million, a price-to-earnings ratio of -14.88 and a beta of 0.90. Trevi Therapeutics has a 1 year low of $2.30 and a 1 year high of $7.39. The stock's 50-day moving average price is $4.30 and its 200-day moving average price is $3.60.
Insider Transactions at Trevi Therapeutics
In other news, insider Farrell Simon sold 81,313 shares of the business's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $6.75, for a total value of $548,862.75. Following the completion of the sale, the insider now owns 76,900 shares of the company's stock, valued at approximately $519,075. The trade was a 51.39 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 24.37% of the company's stock.
Institutional Investors Weigh In On Trevi Therapeutics
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Frazier Life Sciences Management L.P. lifted its stake in shares of Trevi Therapeutics by 44.5% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 10,664,774 shares of the company's stock valued at $43,939,000 after acquiring an additional 3,283,684 shares during the last quarter. Point72 Asset Management L.P. bought a new position in Trevi Therapeutics during the 4th quarter valued at approximately $17,099,000. Vivo Capital LLC raised its position in Trevi Therapeutics by 116.3% during the 4th quarter. Vivo Capital LLC now owns 3,487,903 shares of the company's stock valued at $14,370,000 after purchasing an additional 1,875,000 shares during the last quarter. Woodline Partners LP raised its position in Trevi Therapeutics by 429.9% during the 4th quarter. Woodline Partners LP now owns 3,212,597 shares of the company's stock valued at $13,236,000 after purchasing an additional 2,606,370 shares during the last quarter. Finally, MPM Bioimpact LLC raised its position in Trevi Therapeutics by 101.2% during the 4th quarter. MPM Bioimpact LLC now owns 3,094,896 shares of the company's stock valued at $12,751,000 after purchasing an additional 1,556,379 shares during the last quarter. Institutional investors own 95.76% of the company's stock.
About Trevi Therapeutics
(
Get Free Report)
Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.
Further Reading
Before you consider Trevi Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Trevi Therapeutics wasn't on the list.
While Trevi Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
